. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Endocrinol Metab Clin North Am. 2020 Dec;49(4):741–757. doi: 10.1016/j.ecl.2020.08.002

Table 7.

Therapeutic Options for Use in McCune-Albright Syndrome & Familial Male-Limited Precocious Puberty

McCune-Albright Syndrome	Mechanism of Action

Females
• Letrozole	Third-generation aromatase inhibitor
• Tamoxifen	Selective estrogen receptor modulator
• Fulvestrant	Estrogen receptor antagonist

Males
• Letrozole	Third-generation aromatase inhibitor
• Anastrozole	Third-generation aromatase inhibitor
• Bicalutamide¹	Non-steroidal androgen receptor antagonist

Familial Male-Limited Precocious Puberty	Mechanism of Action

Aromatase Inhibitor
• Letrozole	Third-generation aromatase inhibitor
• Anastrozole	Third-generation aromatase inhibitor

Antiandrogen¹
• Bicalutamide	Non-steroidal androgen receptor antagonist
• Spironolactone	Weak anti-androgenic agent

Used in combination with an aromatase inhibitor.